MARKET

MRNA

MRNA

Moderna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

147.10
-3.07
-2.04%
Opening 12:53 02/24 EST
OPEN
150.41
PREV CLOSE
150.17
HIGH
151.00
LOW
145.18
VOLUME
4.68M
TURNOVER
--
52 WEEK HIGH
189.26
52 WEEK LOW
18.30
MARKET CAP
58.21B
P/E (TTM)
-90.8810
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
U.S. is ready to roll out J&J vaccine 'without delay,' pending FDA clearance, Biden health officials say
CNBC.com · 55m ago
Moderna Q4 2020 Earnings Preview
Moderna (NASDAQ:MRNA) is scheduled to announce Q4 earnings results on Thursday, February 25th, before market open.The consensus EPS Estimate is -$0.36 (+2.7% Y/Y) and the consensus Revenue Estimate is $279.41M
Seekingalpha · 1h ago
Top-Ranked Horizon Therapeutics Hits Key RS Rating Benchmark
Investor's Business Daily · 1h ago
Global COVID cases fall for a sixth straight week as hopes for J&J vaccine are bolstered by FDA data
The U.S. Food and Drug Administration said Wednesday the vaccine developed by Johnson & Johnson appears safe in inoculating against the coronavirus-borne...
MarketWatch · 2h ago
Johnson & Johnson Nabs FDA Endorsement For Covid Shot Ahead Of Key Meeting
Investor's Business Daily · 2h ago
These are the most common side effects from J&J's one-shot Covid vaccine
Roughly 40% of people who took J&J's Covid vaccine reported headaches and just over 38% reported feeling fatigued, the FDA staff said.
CNBC.com · 2h ago
Drugmakers are ramping up Covid vaccine production after fixing initial manufacturing delays
"We've been in the process of developing a manufacturing process for a vaccine product that we've never made before," Pfizer Chief Business Officer John Young said.
CNBC.com · 3h ago
FDA staff endorses Johnson & Johnson’s single-shot Covid vaccine for emergency use
The FDA's staff endorsed Johnson & Johnson's Covid-19 vaccine for emergency use, a critical step in bringing a third shot to the U.S. marketplace.
CNBC.com · 4h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRNA. Analyze the recent business situations of Moderna through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRNA stock price target is 160.38 with a high estimate of 215.00 and a low estimate of 80.00.
EPS
Institutional Holdings
Institutions: 834
Institutional Holdings: 201.51M
% Owned: 50.92%
Shares Outstanding: 395.71M
TypeInstitutionsShares
Increased
220
33.31M
New
252
5.88M
Decreased
179
41.31M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.70%
Pharmaceuticals & Medical Research
+1.40%
Key Executives
Non-Executive Chairman/Co-Founder/Independent Director
Noubar Afeyan
President
Stephen Hoge
Chief Executive Officer/Director
Stephane Bancel
Chief Financial Officer
David Meline
Chief Human Resource Officer
Tracey Franklin
Chief Technology Officer
Juan Andres
General Counsel/Secretary
Lori Henderson
Other
Marcello Damiani
Other
Tal Zaks
Other
Ray Jordan
Other
Jose Vega
Other
Tal Zvi Zaks
Director
Elizabeth Tallett
Non-Executive Independent Director
Stephen Berenson
Non-Executive Independent Director
Robert Langer
Non-Executive Independent Director
Francois Nader
Non-Executive Independent Director
Israel Ruiz
Non-Executive Independent Director
Paul Sagan
  • Dividends
  • Splits
  • Insider Activity
No Data
About MRNA
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Webull offers kinds of Moderna Inc stock information, including NASDAQ:MRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRNA stock methods without spending real money on the virtual paper trading platform.